Novartis Q1 2025 Earnings Report $107.54 +4.14 (+4.01%) Closing price 04/11/2025 03:59 PM EasternExtended Trading$107.09 -0.45 (-0.42%) As of 04/11/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Novartis EPS ResultsActual EPSN/AConsensus EPS $2.07Beat/MissN/AOne Year Ago EPSN/ANovartis Revenue ResultsActual RevenueN/AExpected Revenue$12.92 billionBeat/MissN/AYoY Revenue GrowthN/ANovartis Announcement DetailsQuarterQ1 2025Date4/22/2025TimeBefore Market OpensConference Call DateTuesday, April 22, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryNVS Profile Remove Ads Novartis Earnings HeadlinesNovartis Stock (NVS) Looks Healthier as it Spends $23B on Ramping Up U.S. ManufacturingApril 11 at 8:05 PM | markets.businessinsider.comNovartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. ManufacturingApril 11 at 3:04 PM | wsj.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 13, 2025 | Porter & Company (Ad)Novartis announces planned $23B investment over five years in U.S.April 11 at 10:03 AM | markets.businessinsider.comNovartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs UncertaintiesApril 11 at 10:03 AM | benzinga.comThis Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.April 11 at 8:28 AM | barrons.comSee More Novartis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novartis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novartis and other key companies, straight to your email. Email Address About NovartisNovartis (NYSE:NVS) engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.View Novartis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Upcoming Earnings The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)The PNC Financial Services Group (4/15/2025)ASML (4/16/2025)CSX (4/16/2025)Abbott Laboratories (4/16/2025)Kinder Morgan (4/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
